CN101612315A - 一种用于调整人体机能的中药复方制剂 - Google Patents
一种用于调整人体机能的中药复方制剂 Download PDFInfo
- Publication number
- CN101612315A CN101612315A CN200910043944A CN200910043944A CN101612315A CN 101612315 A CN101612315 A CN 101612315A CN 200910043944 A CN200910043944 A CN 200910043944A CN 200910043944 A CN200910043944 A CN 200910043944A CN 101612315 A CN101612315 A CN 101612315A
- Authority
- CN
- China
- Prior art keywords
- chinese medicinal
- medicinal preparation
- cordyceps
- human body
- ganoderma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 49
- 238000002360 preparation method Methods 0.000 title claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 49
- 241000190633 Cordyceps Species 0.000 claims abstract description 33
- 241000222336 Ganoderma Species 0.000 claims abstract description 30
- 244000293323 Cosmos caudatus Species 0.000 claims abstract description 27
- 235000005956 Cosmos caudatus Nutrition 0.000 claims abstract description 27
- 241000241413 Propolis Species 0.000 claims abstract description 27
- 229940069949 propolis Drugs 0.000 claims abstract description 27
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 26
- 229940079593 drug Drugs 0.000 claims abstract description 25
- 239000002671 adjuvant Substances 0.000 claims description 17
- 210000003734 kidney Anatomy 0.000 abstract description 13
- 210000000952 spleen Anatomy 0.000 abstract description 10
- 210000005036 nerve Anatomy 0.000 abstract description 7
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 27
- 239000000843 powder Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000008187 granular material Substances 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002674 ointment Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000201295 Euphrasia Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000475481 Nebula Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000005325 percolation Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 150000004056 anthraquinones Chemical class 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 2
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000008925 spontaneous activity Effects 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010049865 Achromotrichia acquired Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 241000382825 Cristaria plicata Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000590988 Danainae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010070245 Foreign body Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000000899 Gutta-Percha Substances 0.000 description 1
- 241000130660 Hepialidae Species 0.000 description 1
- 241000330899 Hepialus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 240000000342 Palaquium gutta Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 235000000405 Pinus densiflora Nutrition 0.000 description 1
- 240000008670 Pinus densiflora Species 0.000 description 1
- 235000011609 Pinus massoniana Nutrition 0.000 description 1
- 241000018650 Pinus massoniana Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000879903 Pteria Species 0.000 description 1
- 241001464055 Pteriidae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000576755 Sclerotia Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000217379 Unionidae Species 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229930182483 coumarin glycoside Natural products 0.000 description 1
- 150000008140 coumarin glycosides Chemical class 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229920000588 gutta-percha Polymers 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 208000016258 weakness Diseases 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于调整人体机能的中药复方制剂,由以下质量百分比的原料药组成:铁皮石斛20-80%、冬虫夏草2-20%、西洋参2-20%、蜂胶2-20%、灵芝2-20%、制何首乌2-20%、茯苓2-20%、杜仲2-20%、珍珠2-20%。本发明的中药复方制剂与现有中药制剂比较,长期服用可以调整人体的各项机能,具有补气健脾、滋阴强肾、固本扶正、安神养颜、延年益寿的特点,且无毒副作用。
Description
技术领域
本发明属于中药,具体涉及一种用于调整人体机能的中药复方制剂。
背景技术
目前,随着生活节奏的加快、市场竞争日趋激烈、社会人口日趋老年化,导致大多数人处于一种亚健康状态。如精神压力的增大,人体的免疫力下降,内分泌失调,气血不足,阴阳失衡,老年病发病率增高等。尽管西药的不断研制和开发,但西药的治疗不能从整体去调整人体的各项机能,往往达不到预期的效果。现在也没有在调整人体的各项机能方面效果满意的中药制剂。
发明内容
本发明的目的是提供一种用于调整人体机能的中药复方制剂。该制剂具有补气健脾、滋阴强肾、固本扶正、安神养颜、延年益寿的特点。
本发明的技术方案是这样实现的:用于调整人体机能的中药复方制剂由以下质量百分比的原料药组成:
铁皮石斛20-80%、冬虫夏草2-20%、西洋参2-20%、蜂胶2-20%、灵芝2-20%、制何首乌2-20%、茯苓2-20%、杜仲2-20%、珍珠2-20%。
本发明的中药复方制剂在上述组分的基础上还可添加乳糖、蔗糖、糊精、可溶性淀粉、蜂蜜、乙醇、滑石粉、硬脂酸镁等辅料加工制成颗粒剂、片剂、丸剂、胶囊剂、口服液、散剂、酒剂或膏剂等制剂。其质量百分比如下:
铁皮石斛20-80%、冬虫夏草2-20%、西洋参2-20%、蜂胶2-20%、灵芝2-20%、制何首乌2-20%、茯苓2-20%、杜仲2-20%、珍珠2-20%、辅料1-30%。
因国家法律规定禁止使用珍稀野生动植物入药生产,铁皮石斛为组培繁育与仿野生栽培获得,冬虫夏草可用虫草菌丝体代替,灵芝可用灵芝孢子粉代替。
本发明的原料药中,铁皮石斛属气生兰科草本植物,明代李时珍的《本草纲目》中记载:除痹下气、补内脏虚劳赢瘦,强阴益精。久服,厚肠胃,补内绝不足。来胃气,长肌肉,益智除惊,轻身延年。当代化学和药理学研究发现,铁皮石斛中含有丰富的多糖成份,具有增长T细胞、B细胞、NK细胞和巨噬细胞功能的作用。铁皮石斛中所含多糖对癌症病人具有明显增强T细胞免疫功能的作用。提高人体的免疫力,以防御外界病源因子的侵袭和清除体内衰老死伤、突变细胞,借以维持机体的生理稳定状态。
冬虫夏草为麦角菌科植物冬虫夏草菌的子座及其寄主蝙蝠蛾科昆虫虫草蝙蝠蛾等的幼虫尸体的复合体,首次记载使用是清代吴仪洛《本草丛新》,性味甘,温。功能补肺益肾,化痰止咳。可用之于久咳虚喘,产后虚弱、阳痿阴冷等“虚”的病症。据研究:冬虫夏草主要含有冬虫夏草素、虫草酸、腺苷和多糖、等成分;冬虫夏草素能抑制链球菌、鼻疽杆菌炭疽杆菌等病菌的生长,又是抗癌的活性物质,对人体的内分泌系统和神经系统有好的调节作用;虫草酸能改变人体微循环,具有明显的降血脂和镇咳祛痰作用;虫草多糖是免疫调节剂,可增强机体对病毒及寄生虫的抵抗力。加了患者的白细胞数目、血清总蛋白、防止血糖降低和胆固醇升高。
西洋参为五加科植物西洋参的干燥根。中医认为西洋参性寒,味甘微苦,入肺、脾经,具有补气养阴、泻火除烦、养胃生津之功能,适用于气阴虚而有火之症,多用于肺热燥咳、气层懒言、四肢倦怠、烦躁易怒、热病后伤阴津液亏损等。现代医学研究证明,西洋参具有抗疲劳、抗衰老、抗休克、提高思维、改善记忆及调节内分泌、增强人体免疫力及改善心血管功能等作用。
蜂胶是蜜蜂用从植物幼芽及树干上采集的树脂,蜜蜂上鄂的分泌物、蜂蜡、少量花粉加工而成的一种具有芳香气味,粘性大的天然混合物,燃烧时有特殊的香味,味微苦涩。蜂胶的主要成分有黄酮、萜稀类、有机酸类、芳香性醛类及多种氨基酸酶、维生素、矿物质等,蜂胶中复杂的有效成分,是优良天然保健品和药物的物质基础。
灵芝为多孔菌科植物紫芝或赤芝的全株。中医认为灵芝性味甘平,入五脏肾,补益全身五脏之气。现代科学研究表明,灵芝的有效成份可分为十大类,包括灵芝多糖、灵芝多肽、三萜类、16种氨基酸(其中含有七种人体必需氨基酸)、蛋白质、甾类、甘露醇、香豆精苷、生物碱、有机酸(主含延胡索酸),以及微量元素Ge、P、Fe、Ca、Mn、Zn、等。
制何首乌,具有补肝肾,益精血,乌须发,生发,强筋骨之功效。主治精血亏虚,头晕眼花,须发早白,腰酸脚软,遗精,崩带等证。现代医学证实,何首乌中的蒽醌类物质,具有降低胆固醇、降血糖、抗病毒、强心、促进胃肠蠕动等作用,还有促进纤维蛋白溶解活性作用,对心脑血管疾病有一定的防治作用;何首乌中所含卵磷脂是脑组织、血细胞和其他细胞膜的组成物质,经常食用何首乌,对神经衰弱、白发、脱发、贫血等病症有治疗作用,因此,可延缓衰老、强身健体、保健心脏。动物实验证明,何首乌还有抗肿瘤作用。同时,现代药理研究发现何首乌含有的卵磷脂、蒽醌衍生物及大黄酚等多种物质,能够抑制胆固醇的升高、减少胆固醇在肠道吸收,可防止胆固醇在组织中沉积,因而能缓解动脉粥样硬化的形成,临床研究证实其降胆固醇及甘油三酯总有效率达80%以上。何首乌还有强壮神经的作用,可健脑益智,能够促进血细胞的生长和发育,有显著的抗衰老作用。
茯苓为多孔菌科真菌茯苓的干燥菌核,多寄生于马尾松或赤松的根部。甘、淡、平、归肺、胃、肾经。功效为败毒抗癌、利水化饮、健脾宁心。菌核含β-茯苓聚糖约占干重93%和三萜类化合物乙酰茯苓酸、茯苓酸、3β-羟基羊毛甾三烯酸。此外,尚含树胶、甲壳质、蛋白质、脂肪、甾醇、卵磷脂、葡萄糖、腺嘌呤、组氨酸、胆碱、β-茯苓聚糖分解酶、脂肪酶、蛋白酶等。
杜仲为杜仲科植物杜仲的树皮。中医认为补肝肾,强筋骨,安胎。治腰脊酸疼,足膝痿弱,小便余沥,阴下湿痒,胎漏欲堕,胎动不安,高血压。杜仲含杜仲胶6~10%,还含糖甙、生物碱、果胶、脂肪、树脂、有机酸、酮糖、维生素C、维生素E,维生素B及β-胡萝卜素等,还含有很多人体必须的微量元素,醛糖、绿原酸。
珍珠为珍珠贝科动物马氏珍珠贝、蚌科动物三角帆蚌或褶纹冠蚌等双壳类动物受刺激形成。中医认为其甘、咸,寒。归心、肝经。具有安神定惊,明目消翳,解毒生肌的功效。用于惊悸失眠,惊风癫痫,目生云翳,疮疡不敛。现代研究证明,珍珠中主含碳酸钙。并含有多种氨基酸:亮氨酸,蛋氨酸,丙氨酸,甘氨酸,谷氨酸,天门冬氨酸等。另外,还含有30多种微量元素、牛磺酸、丰富的维生素、肽类。
本发明中药复方制剂以铁皮石斛为君药,滋肺胃之阴,清热生津,主用于阴伤津亏,口干烦渴,食少干呕,病后虚热,目暗不明。方中西洋参补气养阴,清热生津;冬虫夏草补肺气益肾,止血化痰;补气安神,止咳平喘;三者既可协同铁皮石斛滋阴之效,又可以使铁皮石斛性凉太过而伤脾胃,为臣药。茯苓利水渗湿、健脾宁心;制何首乌,补肝肾,益精血,乌须发,生发,强筋骨;杜仲补肝肾,强筋骨,安胎;珍珠安神定惊,明目消翳,解毒生肌;四者协同君、臣药起健脾、宁心、补肝肾、明目、养颜之功效;为佐药;蜂胶为新资源食品,能提高人体的免疫力。以上诸药合用,共奏补气健脾、滋阴强肾、固本扶正、安神养颜、延年益寿之功。
本发明所称制剂是通过下列步骤完成的:
1、精选铁皮石斛、冬虫夏草、西洋参、蜂胶、珍珠、灵芝,单独或混合粉碎(粉碎方法可以是普通机械粉碎过200目筛,也可以是用超微粉碎机粉碎至微粉化),备用。
2、精选制何首乌、茯苓、杜仲,切成饮片或打成粗粉,依次加入八倍水、六倍水量进行提取2小时、1.5小时,过滤,合并提取液;提取液减压浓缩至相对比重为1.10备用。
3、若制备成片剂、胶囊、丸剂,取2的浓缩液喷雾干燥,再与1的药粉混合均匀,加入辅料加工制成。
4、若制成颗粒剂、散剂,取2的浓缩液喷雾干燥,再取1的微粉混合均匀,加入辅料加工制成。
5、若制成口服液、酒剂、膏剂,取1的药粉,加水或一定浓度的乙醇进行浸渍或渗漉或煎煮、过滤、浓缩,再与2的的浓缩液混合、搅拌均匀,加入辅料加工制成。
本发明的中药复方制剂的用药方法为:
按中药复方生药材总量计算,根据服用人的体质、机能情况,口服,日服用20-50g,分二或三次服用。
本发明的中药复方制剂,根据现代药理试验研究表明:
给小鼠ig.0.625g、1.25g、2.5g/kg本发明颗粒剂,每日两次,连续一周,可显著增强小鼠的耐缺氧能力。在1.25g/kg剂量下,可增强小鼠的自发活动,而在2.5g/kg的剂量下,可减少小鼠的自发活动,对小鼠中枢神经系统产生双向调节作用,在上述相同剂量下,尚可延长小鼠戍巴比妥钠睡眠时间和促进胃肠蠕动,开胃健脾。本发明颗粒剂0.05、0.15g/0.2ml/只,可显著增加家兔离体心脏冠脉输出量,改善心肌供血;给小鼠ig 1.25g、2.5g/kg本发明颗粒剂,每日两次,连续一周,可明显增强小鼠的免疫功能,连给4周,可产生抗自由基作用,延缓小鼠的衰老过程。
本发明颗粒剂的急性毒性试验表明:本品未测出LD50,小鼠最大耐受剂量为240g/kg/日,连续观察七天,20只小鼠全部存活,未出现异常反应。本发明颗粒剂给小鼠灌胃给药的最大耐受倍数为成人每日口服量的3000倍。
本发明颗粒剂的长期毒性试验结果表明:给大鼠ig本发明颗粒剂5、10g/kg,分别相当于临床成人每日用量的25和50倍,每日一次,连续8周,对大鼠生长发育、活动行为、血象、肝、肾功能及病理检查等均无明显毒性反应。
本发明的中药复方制剂与现有中药制剂比较,长期服用可以调整人体的各项机能,具有补气健脾、滋阴强肾、固本扶正、安神养颜、延年益寿的特点,且无毒副作用。
本发明的中药复方制剂在给39名体质弱,易反复感冒的人服用一个月后,体质明显增强。经三个月随访,39名中无一人患感冒。
47名肠胃虚弱,或溃疡,或便溏,或大便次数偏多的人服用本发明的中药复方制剂一个月后,肠胃功能基本恢复,无肠胃疼痛发生,溃疡基本愈合,大便形态与次数均正常。经三个月随访,46名中无一人复发肠胃疾病,其中有一名因食用不洁食物引起腹泻。
26名有消渴症(西医称为糖尿病)的人服用本发明的中药复方制剂三个月后,消渴症状基本消失,视物模糊明显改善,其中19名血糖、尿糖检查均恢复正常。
61名气阴两虚型慢性咽喉炎人服用本发明的中药复方制剂半个月后,全部人员咽部异物感消失;服用一个月后,精神状态明显改善,睡眠良好,食欲增强。
23名脸部有红肿型粉刺的人服用本发明的中药复方制剂一周后,21名的脸部红肿明显消褪,仅余突出状油脂分泌物。
31名脸部有黄褐斑的妇女服用本发明的中药复方制剂二个月后,27名妇女黄褐斑明显变淡,精神状态良好,现继续服用。
具体实施方式
实施例1
本发明的中药复方汤剂,其原料药复方成分质量百分比为:
铁皮石斛20%、冬虫夏草5%、西洋参5%、蜂胶5%、灵芝10%、制何首乌20%、茯苓20%、杜仲10%、珍珠5%。
实施例2
本发明的中药复方汤剂,其原料药复方成分质量百分比为:
铁皮石斛20%、冬虫夏草20%、西洋参20%、蜂胶4%、灵芝4%、制何首乌4%、茯苓4%、杜仲4%、珍珠20%。
实施例3
本发明的中药复方汤剂,其原料药复方成分质量百分比为:
铁皮石斛20%、冬虫夏草4%、西洋参4%、蜂胶20%、灵芝20%、制何首乌20%、茯苓4%、杜仲4%、珍珠4%。
精选上述实施例1-3的中药原料,总量为50g,加8倍量水,浸泡半小时,加热至沸后,煎煮一个小时,取汁;再加6倍量水,加热至沸,煎煮半小时,取汁;合并一、二次的药汁搅拌均匀,即得汤剂。前述汤剂分三次一日服完。
实施例4
本发明的中药复方汤剂,其原料药复方成分质量百分比为:
铁皮石斛20%、冬虫夏草10%、西洋参10%、蜂胶5%、灵芝5%、制何首乌5%、茯苓20%、杜仲20%、珍珠5%。
实施例5
本发明的中药复方汤剂,其原料药复方成分质量百分比为:
铁皮石斛50%、冬虫夏草5%、西洋参5%、蜂胶6%、灵芝6%、制何首乌10%、茯苓10%、杜仲6%、珍珠2%。
实施例6
本发明的中药复方汤剂,其原料药复方成分质量百分比为:
铁皮石斛80%、冬虫夏草2%、西洋参2%、蜂胶2%、灵芝2%、制何首乌2%、茯苓2%、杜仲2%、珍珠6%。
精选上述实施例4-6的中药原料,总量为50g,冬虫夏草、西洋参、珍珠打成细粉备用,其余中药加8倍量水,浸泡半小时,加热至沸后,煎煮一个小时,取汁;再加6倍量水,加热至沸,煎煮半小时,取汁;合并一、二次的药汁搅拌均匀,即得汤剂。前述细粉用汤剂分三次冲服,一日服完。
实施例7
本发明的中药复方制剂颗粒剂,其原料药复方成分的质量百分比为:
铁皮石斛80%、冬虫夏草2%、西洋参2%、蜂胶2%、灵芝2%、制何首乌2%、茯苓2%、杜仲2%、珍珠2%、辅料4%(乳糖∶可溶性淀粉=1∶1)。
实施例8
本发明的中药复方制剂颗粒剂,其原料药复方成分的质量百分比为:
铁皮石斛20%、冬虫夏草20%、西洋参20%、蜂胶20%、灵芝2%、制何首乌2%、茯苓2%、杜仲2%、珍珠2%、辅料10%(乳糖∶可溶性淀粉=1∶1)。
实施例9
本发明的中药复方制剂颗粒剂,其原料药复方成分的质量百分比为:
铁皮石斛20%、冬虫夏草2%、西洋参2%、蜂胶2%、灵芝20%、制何首乌20%、茯苓20%、杜仲2%、珍珠2%、辅料10%(乳糖∶可溶性淀粉=1∶1)。
实施例10
本发明的中药复方制剂颗粒剂,其原料药复方成分的质量百分比为:
铁皮石斛20%、冬虫夏草5%、西洋参5%、蜂胶5%、灵芝5%、制何首乌5%、茯苓5%、杜仲20%、珍珠20%、辅料10%(乳糖∶可溶性淀粉=1∶1)。
上述实施例7-10的中药复方制剂颗粒剂通过下列步骤生产加工:
1、精选铁皮石斛、冬虫夏草、西洋参、蜂胶、珍珠、灵芝,用超微粉碎机粉碎至微粉化,备用;
2、精选制何首乌、茯苓、杜仲,切成饮片或打成粗粉,依次加入八倍水、六倍水量进行提取2小时、1.5小时,过滤,合并提取液;提取液减压浓缩至相对比重为1.10,将浓缩液喷雾干燥得浸膏细粉,备用;
3、取2的浸膏细粉,再与1的药物微粉混合均匀,喷雾加入前述物料5%的乙醇,制粒、干燥、20目整粒,得到颗粒;包装即得颗粒制。
实施例11
本发明的中药复方制剂膏剂,其原料药复方成分的质量百分比为:
铁皮石斛20%、冬虫夏草5%、西洋参5%、蜂胶5%、灵芝5%、制何首乌20%、茯苓10%、杜仲10%、珍珠5%、辅料15%(蜂蜜∶蔗糖=4∶1)。
其制备工艺按下列步骤生产加工:
1、精选铁皮石斛、冬虫夏草、西洋参、蜂胶、珍珠、灵芝,粉碎,过筛;在药粉中依次加入8倍量、6倍量水,煎煮,过滤,合并滤液,减压浓缩至相对比重为1.10,备用。
2、精选制何首乌、茯苓、杜仲,切成饮片或打成粗粉,依次加入8倍水、6倍水量进行提取2小时、1.5小时,过滤,合并提取液;提取液减压浓缩至相对比重为1.10备用。
3、取1、2药液合并混合均匀,减压浓缩至相对比重为1.45,加入上述药物生药材总重15%辅料(蜂蜜∶蔗糖=4∶1),搅拌使混合均匀,加热浓缩至相对比重为1.50左右的膏滋,灭菌、灌装、包装即得膏剂。
实施例12
本发明的中药复方制剂膏剂,其原料药复方成分的质量百分比为:
铁皮石斛40%、冬虫夏草2%、西洋参2%、蜂胶2%、灵芝2%、制何首乌10%、茯苓5%、杜仲5%、珍珠2%、辅料30%(蜂蜜∶蔗糖=5∶1)。
其制备工艺按下列步骤生产加工:
1、精选铁皮石斛、冬虫夏草、西洋参、蜂胶、珍珠、灵芝,粉碎,过筛;药粉混合均匀,用30倍量80%乙醇用渗漉法提取,回收乙醇浓缩至相对比重为1.20;前述已渗漏药物再依次加入8倍量、6倍量水,煎煮2小时、1.5小时,过滤,合并滤液,减压浓缩至相对比重为1.10,备用。
2、精选制何首乌、茯苓、杜仲,切成饮片或打成粗粉,依次加入八倍水、六倍水量进行提取2小时、1.5小时,过滤,合并提取液;提取液减压浓缩至相对比重为1.10备用。
3、取1、2水提药液合并混合均匀,浓缩至相对比重为1.4。
4、取1的乙醇渗漉浸膏与3的水提浸膏合并混合均匀,加入30%辅料(蜂蜜∶蔗糖=5∶1),搅拌使混合均匀,灭菌、灌装、包装即得膏剂。
实施例13
本发明的中药复方制剂胶囊剂,其原料药复方成分的重量百分比为:铁皮石斛60%、冬虫夏草5%、西洋参5%、蜂胶5%、灵芝5%、制何首乌5%、茯苓5%、杜仲5%、珍珠4%、辅料1%(滑石粉∶硬脂酸镁=1∶1)。
其制备工艺按下列步骤生产加工:
1、精选铁皮石斛、冬虫夏草、西洋参、蜂胶、珍珠、灵芝,用超微粉碎机粉碎至微粉化,备用;
2、精选制何首乌、茯苓、杜仲,切成饮片或打成粗粉,依次加入八倍水、六倍水量进行提取2小时、1.5小时,过滤,合并提取液;提取液减压浓缩至相对比重为1.10,将浓缩液喷雾干燥得浸膏细粉,备用;
3、取2的浸膏细粉,再与1的药物微粉混合均匀,加入1%辅料(滑石粉∶硬脂酸镁=1∶1),混合均匀,装填胶囊,包装即得胶囊剂。
Claims (2)
1、一种用于调整人体机能的中药复方制剂,其特征是由以下质量百分比的原料药组成:
铁皮石斛20-80%、冬虫夏草2-20%、西洋参2-20%、蜂胶2-20%、灵芝2-20%、制何首乌2-20%、茯苓2-20%、杜仲2-20%、珍珠2-20%。
2、一种用于调整人体机能的中药复方制剂,其特征是由以下质量百分比的原料药组成:
铁皮石斛20-80%、冬虫夏草2-20%、西洋参2-20%、蜂胶2-20%、灵芝2-20%、制何首乌2-20%、茯苓2-20%、杜仲2-20%、珍珠2-20%、辅料1-30%。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910043944A CN101612315A (zh) | 2009-07-22 | 2009-07-22 | 一种用于调整人体机能的中药复方制剂 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910043944A CN101612315A (zh) | 2009-07-22 | 2009-07-22 | 一种用于调整人体机能的中药复方制剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101612315A true CN101612315A (zh) | 2009-12-30 |
Family
ID=41492324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910043944A Pending CN101612315A (zh) | 2009-07-22 | 2009-07-22 | 一种用于调整人体机能的中药复方制剂 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101612315A (zh) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101971941A (zh) * | 2010-09-10 | 2011-02-16 | 芮旭婷 | 一种复合石槲保健品的配制方法 |
| CN102240365A (zh) * | 2010-05-14 | 2011-11-16 | 湖南瑞丹科技有限公司 | 增强机体免疫力的药物组合物及其制备方法 |
| CN102670991A (zh) * | 2012-05-14 | 2012-09-19 | 贵州省赤水市金钗石斛产业开发有限公司 | 一种金钗石斛浸膏的制备方法 |
| CN103071056A (zh) * | 2013-01-09 | 2013-05-01 | 普洱市民族传统医药研究所 | 一种用于治疗咽喉炎症的药物 |
| CN103637182A (zh) * | 2013-11-01 | 2014-03-19 | 胡安然 | 一种免疫力低患者的特殊膳食 |
| CN104287031A (zh) * | 2014-07-29 | 2015-01-21 | 汤兴华 | 一种安神补气石斛口服液 |
| CN104705442A (zh) * | 2015-03-31 | 2015-06-17 | 吴绍平 | 铁皮石斛茶及其制备方法 |
| CN106075338A (zh) * | 2016-07-06 | 2016-11-09 | 湖南净初社区健康科技有限公司 | 保健中药组合物及其制备方法和应用 |
| CN107485685A (zh) * | 2017-09-29 | 2017-12-19 | 南京仙草堂生物科技有限公司 | 一种基于铁皮石斛的中药制剂的制备方法 |
| CN107853700A (zh) * | 2017-11-28 | 2018-03-30 | 爱可道生物科技有限公司 | 一种朝鲜蓟保肝抗疲劳药物组合物 |
| CN108721505A (zh) * | 2018-06-19 | 2018-11-02 | 泸州德高生物科技有限公司 | 绿色铁皮石斛膏滋剂的制备方法 |
-
2009
- 2009-07-22 CN CN200910043944A patent/CN101612315A/zh active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102240365A (zh) * | 2010-05-14 | 2011-11-16 | 湖南瑞丹科技有限公司 | 增强机体免疫力的药物组合物及其制备方法 |
| CN101971941A (zh) * | 2010-09-10 | 2011-02-16 | 芮旭婷 | 一种复合石槲保健品的配制方法 |
| CN102670991B (zh) * | 2012-05-14 | 2013-07-31 | 贵州省赤水市金钗石斛产业开发有限公司 | 一种金钗石斛浸膏的制备方法 |
| CN102670991A (zh) * | 2012-05-14 | 2012-09-19 | 贵州省赤水市金钗石斛产业开发有限公司 | 一种金钗石斛浸膏的制备方法 |
| CN103071056B (zh) * | 2013-01-09 | 2014-06-18 | 普洱市民族传统医药研究所 | 一种用于治疗咽喉炎症的药物 |
| CN103071056A (zh) * | 2013-01-09 | 2013-05-01 | 普洱市民族传统医药研究所 | 一种用于治疗咽喉炎症的药物 |
| CN103637182A (zh) * | 2013-11-01 | 2014-03-19 | 胡安然 | 一种免疫力低患者的特殊膳食 |
| CN104287031A (zh) * | 2014-07-29 | 2015-01-21 | 汤兴华 | 一种安神补气石斛口服液 |
| CN104705442A (zh) * | 2015-03-31 | 2015-06-17 | 吴绍平 | 铁皮石斛茶及其制备方法 |
| CN106075338A (zh) * | 2016-07-06 | 2016-11-09 | 湖南净初社区健康科技有限公司 | 保健中药组合物及其制备方法和应用 |
| CN107485685A (zh) * | 2017-09-29 | 2017-12-19 | 南京仙草堂生物科技有限公司 | 一种基于铁皮石斛的中药制剂的制备方法 |
| CN107853700A (zh) * | 2017-11-28 | 2018-03-30 | 爱可道生物科技有限公司 | 一种朝鲜蓟保肝抗疲劳药物组合物 |
| CN108721505A (zh) * | 2018-06-19 | 2018-11-02 | 泸州德高生物科技有限公司 | 绿色铁皮石斛膏滋剂的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101612315A (zh) | 一种用于调整人体机能的中药复方制剂 | |
| CN101695376B (zh) | 预防糖尿病的保健食品 | |
| CN104799146A (zh) | 一种改善亚健康的功能性营养食品组合及其制备方法 | |
| CN112121144B (zh) | 一种刺梨组合物及其制备方法和用途 | |
| CN103103099B (zh) | 一种复方霍斛蓉芝保健酒及生产工艺 | |
| CN103585261A (zh) | 玛咖人参片及其制备方法 | |
| CN105942498A (zh) | 具有治疗糖尿病作用的功能性营养食品组合及其制备方法 | |
| CN105695258A (zh) | 一种含荔枝核皂苷的女性保健酒 | |
| CN105454576A (zh) | 茉莉花八宝茶及其制备方法 | |
| CN103099833A (zh) | 有助于缓解运动疲劳和延缓衰老的软胶囊及其制备方法 | |
| CN107751993A (zh) | 一种抗疲劳膏滋及其制备方法 | |
| CN108813501B (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
| KR101771090B1 (ko) | 식품원료로 분류되는 한약재를 이용한 체온상승용 조성물 및 이의 제조방법 | |
| CN108175785A (zh) | 金花葵复合保健饮品及其制备方法 | |
| CN101336965B (zh) | 一种用于改善糖耐量、降低血糖的中成药及其制备方法 | |
| CN103610077A (zh) | 一种海参胶囊 | |
| CN114404517A (zh) | 一种用于痛风和降低尿酸的组合物及其用途与制备方法 | |
| KR102659842B1 (ko) | 차전자피 및 복합추출물을 포함하는 장 기능 개선 및 배변 촉진용 건강기능식품 조성물 및 이의 제조방법 | |
| CN105748823A (zh) | 一种美容养颜中药组合物及其制备方法 | |
| CN101564431B (zh) | 一种强身抗疲劳抗衰老的中药制剂及其制作方法 | |
| CN106177166A (zh) | 一种具有缓解体力疲劳功能的组合物及其制备方法 | |
| CN100435827C (zh) | 补肝肾抗衰老降三高营养中药品及制备方法 | |
| CN110226721A (zh) | 一种具有辅助降血糖功能的组合物 | |
| KR20200061446A (ko) | 함초를 이용한 식품 조성물 및 그 제조방법 | |
| CN113456778A (zh) | 一种提升能量的组合物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091230 |